制药巨头诺华公司(Novartis)决定终止针对遗传性心血管风险的心脏病药物 Pelacarsen 的研发项目 1234。这一决定源于该药物在关键临床试验中意外失败,未能有效预防心脏病发作或中风 124。Pelacarsen 此前被医学界寄予厚望,甚至被视为极具潜力的“稳赢”疗法,旨在降低特定遗传因素带来的心脏健康风险 34。
该药物的研发失败令许多医生和心脏病专家感到震惊 124。尽管业界原本对该类新药抱有极高期望,但最终结果显示其无法达到预期的临床终点 23。此次挫折标志着针对特定脂质靶点的治疗尝试遭遇重大挫折,打破了外界对于该药物作为突破性疗法的乐观预期 3。
Pharmaceutical giant Novartis has abandoned the development of its heart medication, Pelacarsen, after the drug failed to prevent heart attacks or strokes in a key clinical trial 1234. The treatment was designed to address inherited cardiovascular risks, but the critical study results did not meet expectations 1234. This failure marks a significant setback for a therapy that had been widely regarded as a promising solution for genetic heart disease risks 234.
The outcome has stunned doctors and cardiologists who held high hopes for the drug’s potential 1234. Pelacarsen was previously considered a likely success, with the medical community anticipating it would effectively reduce major cardiovascular events 24. The decision to halt the program underscores the unpredictability of drug development, even for treatments viewed as strong candidates prior to final data 3.
评论
还没有评论,欢迎留下第一条。